Vir Biotechnology
NasdaqGS:VIR Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
AN
Consensus Narrative from 8 Analysts
Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success
Key Takeaways ECLIPSE Phase III program in hepatitis delta and oncology advancements promise revenue and earnings growth through new treatments and diversified revenue streams. Restructuring to reduce expenses and strategic capital allocation enhance financial stability, ensuring long-term sustainability and support for clinical development.
View narrativeUS$32.00
FV
77.5% undervalued intrinsic discount-4.47%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
2 days ago author updated this narrative